Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Sook-Kyoung, Noh, Eui-Kyu, Yu, Ho-Min, Kim, Do Kyoung, Seo, Hye Jin, Lee, Yoo Jin, Cheon, Jaekyung, Koh, Su Jin, Min, Young Joo, Choi, Yunsuk, Jo, Jae-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718665/
https://www.ncbi.nlm.nih.gov/pubmed/33276759
http://dx.doi.org/10.1186/s12885-020-07701-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718665/
https://www.ncbi.nlm.nih.gov/pubmed/33276759
http://dx.doi.org/10.1186/s12885-020-07701-8

Ejemplares similares